A promising medication, retatrutide, is creating considerable excitement in the country as a potential option for obesity. Developed by Eli Lilly, this medicine combines the effects of two glucagon-like peptide-1 (GLP-1) receptor agonists and an glucose-dependent insulinotropic polypeptide (GIP) target agonist, aiming to better regulate hunger a… Read More